MIRA Pharmaceuticals Announces Promising Preclinical Results for Ketamir-2

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) has revealed new preclinical results for its oral ketamine analog, Ketamir-2. The data highlights Ketamir-2's potential in treating neurological and neuropsychiatric disorders, including depression, treatment-resistant depression (TRD), and post-traumatic stress disorder (PTSD).

Ketamir-2 demonstrates improved brain penetration by avoiding interaction with P-glycoprotein (P-gp). This could lead to better oral absorption and higher efficacy compared to traditional ketamine. Ketamir-2's oral formulation offers greater convenience, potentially improving patient compliance.

Preclinical studies predict an oral bioavailability of around 80% for Ketamir-2, significantly higher than traditional ketamine. The compound appears safe at high doses and shows no interaction with the mu-opioid receptor, possibly reducing opioid-related side effects.

MIRA is exploring Ketamir-2's efficacy in treating chemotherapy-induced depression and cancer-related neuropathic pain. The company aims to submit an Investigational New Drug application to the FDA by the end of the year to initiate human trials.

MIRA's CEO, Erez Aminov, asserted that Ketamir-2 could transform treatments for debilitating conditions, while Dr. Itzchak Angel emphasized its potential as a groundbreaking mental health treatment.